TruScreen Half Year Report and Interim Financial Statements

Published: 31 January 2018

TruScreen Limited has provided a copy of its 2018 Interim Report for the six months ended 30 September 2017. The report is available for viewing on the company website


For more information visit or contact:

Martin Dillon 
TruScreen Chief Executive Officer

Media Liaison
Jackie Ellis
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.